Do IL6R rs2228145 and IL6 rs1800795 variants alter inflammatory responsiveness?

Human immune responsiveness is highly individualized, shaped significantly by genetic variations that alter the interleukin-6 (IL-6) pathway. Two key polymorphisms—IL6R rs2228145 and IL6 rs1800795—directly drive these differences by altering receptor dynamics and gene transcription.

Mechanistic pathways of IL-6 regulation

• Receptor shedding and trans-signaling: The IL6R rs2228145 (Asp358Ala) variant enhances proteolytic cleavage of membrane-bound IL-6 receptor (mIL-6R) by sheddases ADAM10 and ADAM17. This process downregulates classical signaling while promoting gp130-mediated trans-signaling in cells lacking native receptors.
• Transcription factor binding: The IL6 rs1800795 (-174 G/C) promoter variant alters the binding affinity of critical transcription factors, including GATA1 and NF-1, directly modulating IL-6 gene expression.

Systemic effects on inflammatory markers

• Dose-dependent biomarker shifts: Each copy of the minor C (Ala358) allele of rs2228145 leads to a 30–35% increase in circulating soluble IL-6R (sIL-6R) and a 10–15% increase in total IL-6, accompanied by a 7–12% decrease in C-reactive protein (CRP) levels. This creates a discordant phenotype that systemically dampens classical IL-6 signaling.
• Stress-induced reactivity: The rs1800795 variant regulates baseline and stress-induced IL-6 and CRP. While the G allele is classically associated with higher baseline transcription, the C allele can drive heightened expression under acute physical stressors such as pancreatitis, exercise, or surgical trauma.

Bottom line

• Strong genetic and mechanistic evidence confirms that IL6R rs2228145 and IL6 rs1800795 are key functional variants that alter signaling pathways and circulating biomarker levels, establishing clear, genetically determined differences in individual inflammatory responsiveness.